NASDAQ:ILMNIllumina Stock Price, Forecast & News

$263.50

-9.49 (-3.48 %)

(As of 04/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$259.45

Now: $263.50▼

$274.33

50-Day Range

$209.62

MA: $266.26▼

$303.20

52-Week Range

$196.78

Now: $263.50▼

$380.76

Volume871,759 shs

Average Volume1.50 million shs

Market Capitalization$38.73 billion

P/E Ratio39.04

Dividend YieldN/A

Beta0.91

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Illumina has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 11 buy ratings, 2 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $322.93, Illumina has a potential upside of 22.6% from its current price of $263.50.
Amount of Analyst Coverage
Illumina has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Illumina has received 1,006 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Illumina has received 894 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Illumina has received 52.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote “Outperform” if you believe ILMN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Illumina does not currently pay a dividend.
Dividend Growth
Illumina does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Illumina insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $399,063.00 in company stock.
Percentage Held by Insiders
Only 0.38% of the stock of Illumina is held by insiders.
Percentage Held by Institutions
92.26% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Illumina are expected to grow by 18.96% in the coming year, from $6.75 to $8.03 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Illumina is 39.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.23.
Price to Earnings Ratio vs. Sector
The P/E ratio of Illumina is 39.04, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.79.
Price to Earnings Growth Ratio
Illumina has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Illumina has a P/B Ratio of 8.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.51 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

Current SymbolNASDAQ:ILMN

Previous Symbol

CUSIP45232710

CIK1110803

Webhttp://www.illumina.com/

Phone858-202-4500

Debt

Debt-to-Equity Ratio0.40

Current Ratio6.69

Quick Ratio6.15

Price-To-Earnings

Trailing P/E Ratio39.04

Forward P/E Ratio39.04

P/E Growth1.9

Sales & Book Value

Annual Sales$3.54 billion

Price / Sales10.93

Cash Flow$8.46 per share

Price / Cash Flow31.16

Book Value$31.38 per share

Price / Book8.40

Profitability

EPS (Most Recent Fiscal Year)$6.57

Net Income$1.00 billion

Net Margins28.27%

Return on Equity22.34%

Return on Assets13.56%

Miscellaneous

Employees7,700

Outstanding Shares147,000,000

Market Cap$38.73 billion

Next Earnings Date4/23/2020 (Estimated)

OptionableOptionable

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock been impacted by COVID-19 (Coronavirus)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ILMN shares have increased by 7.1% and is now trading at $263.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Illumina?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Illumina.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Illumina.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Wednesday, January, 29th. The life sciences company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.58 by $0.12. The life sciences company earned $953 million during the quarter, compared to analyst estimates of $950.16 million. Illumina had a return on equity of 22.34% and a net margin of 28.27%. The company's revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the company earned $1.32 earnings per share. View Illumina's earnings history.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY20 earnings guidance on Wednesday, January, 29th. The company provided earnings per share guidance of $6.80-7.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.98. The company issued revenue guidance of $3.86-3.93 billion, compared to the consensus revenue estimate of $3.92 billion.

What price target have analysts set for ILMN?

15 Wall Street analysts have issued twelve-month price objectives for Illumina's stock. Their forecasts range from $245.00 to $380.00. On average, they expect Illumina's stock price to reach $322.93 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View analysts' price targets for Illumina.

What are Wall Street analysts saying about Illumina stock?

Here are some recent quotes from research analysts about Illumina stock:

1. According to Zacks Investment Research, "Over the past year, Illumina’s shares have outperformed the industry it belongs to. It is encouraging to note that revenues grew across the company’s high and low throughput categories. Illumina continues with its robust performance across a broad range of sequencing applications. NovaSeq outpaced HiSeq X to become the most sequencing data generating platform, repeating its past performance on an annualized basis. The launch of AncestryHealth Plus and the partnership with QIAGEN N.V, the Broad Institute of MIT and Harvard in the third quarter also buoy optimism. It posted solid results in the third quarter of 2019, with earnings and revenues beating the Zacks Consensus Estimate. On the flip side, contraction in both research and development expenses and selling, general & administrative expenses are concerning for the company." (1/20/2020)
2. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019)

Has Illumina been receiving favorable news coverage?

Media headlines about ILMN stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutIllumina.

Who are some of Illumina's key competitors?

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), Baidu (BIDU), Visa (V), Micron Technology (MU), Adobe (ADBE) and Gilead Sciences (GILD).

Who are Illumina's key executives?

Illumina's management team includes the following people:

Mr. Jay T. Flatley, Exec. Chairman (Age 66)
Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different institutional and retail investors. Top institutional investors include Private Asset Management Inc. (0.01%), Bath Savings Trust Co (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View institutional ownership trends for Illumina.

Which major investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC, Private Asset Management Inc., and Bath Savings Trust Co. View insider buying and selling activity for Illumina.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $263.50.

How big of a company is Illumina?

Illumina has a market capitalization of $38.73 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe. View additional information about Illumina.

What is Illumina's official website?

The official website for Illumina is http://www.illumina.com/.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: Most Active Stocks: Dollar Volume vs Share Volume

NASDAQ:ILMNIllumina Stock Price, Forecast & News

Adding

Adding

Adding Illumina, Inc.

Beat the Market (BTM) Rank™

3.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage